Anixa Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANIX research report →
Range $6 – $6
Price Chart
About the company
Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases.
- CEO
- Amit Kumar
- IPO
- 1983
- Employees
- 4
- HQ
- San Jose, CA, US
Get TickerSpark's AI analysis on ANIX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $84.82M
- P/E
- -7.97
- Fwd P/E
- 1.49
- PEG
- 0.01
- P/S
- 0.00
- P/B
- 5.74
- EV/EBITDA
- -7.89
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -70.44%
- ROIC
- -82.06%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-36,000+0.0%
- Op Income
- $-11,701,000
- Net Income
- $-10,927,000+13.0%
- EPS
- $-0.34+12.8%
- OCF Growth
- +2.2%
- FCF Growth
- +2.2%
- 52W High
- $5.46
- 52W Low
- $2.32
- 50D MA
- $2.85
- 200D MA
- $2.95
- Beta
- 0.60
- RSI (14)
- 37
- Avg Volume
- 282.29K
No earnings-call transcripts are available for ANIX yet.
- Free Float
- 94.4%
- Shares Outstanding
- 34.76M
- Float Shares
- 32.81M
of shares held by institutions
67 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 1.46M | ▲ 37.23K |
| Vanguard Capital Management LLC | 1.33M | 0 |
| Marshall Wace, Llp | 808.45K | ▲ 480.12K |
| Laird Norton Wetherby Trust Company, LLC | 600.73K | ▲ 22.00K |
| Ubs Group AG | 586.82K | ▲ 1.39K |
| D.A. Davidson & Co. | 494.95K | ▼ 44.32K |
| Geode Capital Management, LLC | 341.64K | ▼ 17.55K |
| Renaissance Technologies LLC | 300.55K | ▲ 241.18K |
| Vanguard Fiduciary Trust Co | 210.21K | ▲ 17.86K |
| Blackrock, Inc. | 194.81K | ▼ 4.95K |
| Gsa Capital Partners Llp | 181.02K | ▲ 63.55K |
| State Street Corp | 159.04K | 0 |
Held by 28 ETFs
Biggest fund positions in ANIX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 30, 26 | KUMAR AMIT | buy | 5,000 |
| Oct 23, 26 | Titterton Lewis H jr | buy | 8,000 |
| Oct 22, 26 | KUMAR AMIT | buy | 8,000 |
| Sep 30, 26 | Catelani Michael | buy | 5,500 |
| Sep 24, 26 | KUMAR AMIT | buy | 7,000 |
| Sep 24, 26 | Baskies Arnold M | buy | 5,000 |
| Sep 23, 26 | Titterton Lewis H jr | buy | 49,036 |
| Sep 10, 26 | KUMAR AMIT | buy | 3,000 |
| Sep 10, 26 | Titterton Lewis H jr | buy | 10,000 |
| Sep 10, 26 | KUMAR AMIT | buy | 5,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ANIX coverage
Recent articles, reports, and earnings notes.
No research on ANIX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ANIX report →Anixa Biosciences Announces Issuance of Canadian Patent Strengthening International Protection for its Ovarian Cancer Vaccine Technology
prnewswire.com · Nov 19
Anixa Biosciences and Curia will Develop Final Formulation for Breast Cancer Vaccine in Preparation for Phase 2 Clinical Trial
prnewswire.com · Nov 18
Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026
prnewswire.com · Nov 4
Anixa Biosciences (NASDAQ:ANIX) Share Price Breaks Below 200-Day Moving Average – Time to Sell?
defenseworld.net · Oct 27
Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial
prnewswire.com · Oct 26
Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference
prnewswire.com · Oct 13
Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial
prnewswire.com · Oct 5
Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial
prnewswire.com · Oct 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.